Integra LifeSciences (IART) reported third-quarter adjusted earnings of $0.59 per share, beating the $0.56 consensus by 5.4% and growing 9.3% from a year ago. Revenue of $411.18 million rose 2.3% but missed the $414.53 million consensus by 0.8%. The beat matters less than the guidance reset around it. Full-year revenue guidance is now $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion in July. Adjusted EPS guidance fell to $2.30 to $2.40 from $2.40 to $2.50. The new outlook sits below Street expectations. Because Integra pre-announced these numbers on October 2, the report confirmed a reset investors had already absorbed. It also ended three quarters of reaffirmed guidance. That is the central tension: a quarter that cleared the EPS bar inside an outlook that keeps getting smaller.

The quality of the beat deserves scrutiny. Adjusted gross margin fell to 61.1% from 62.9% a year earlier and was roughly flat with the second quarter's 61.3%. Adjusted EBITDA margin slipped to 19.4% from 19.5%. Adjusted EPS growth came mainly from expense control, with SG&A and R&D both lower year over year, rather than from operating leverage on revenue. The $0.59 also landed inside the company's own $0.53 to $0.61 range, so this was not a breakout quarter. GAAP EPS of $0.19 compares with a $0.07 loss a year ago. However, that swing was helped by $14.7 million of other income, which included Cincinnati-related insurance and acquisition-related items.

The segment mix was sharply divided. Neurosurgery grew 6.5% organically, up from 1.9% in each of the first two quarters, despite roughly $7 million of flood-related lost revenue. International specialty surgery grew 7.8%. Those results show the core franchise has real demand. Tissue Reconstruction is going the other way. It fell 2.2% after a 2% decline in the second quarter and 6.4% growth in the first. Management now expects the segment to be roughly flat for 2026, versus low-to-mid single-digit growth guided in February. The causes are competitive rather than temporary:

• MicroMatrix is losing share to powder-form entrants, with sales-force turnover adding pressure.
• Integra Skin is recapturing burn accounts more slowly, and price concessions may be needed.
• Base tissue reconstruction is expected to be flat again in 2027.

The Cincinnati flood is the larger credibility problem. Management called it immaterial in July. The company now expects lost revenue of $15 to $20 million in the fourth quarter and a similar amount in the first quarter of 2027. Full manufacturing is not expected until the second quarter of 2027, and the outlook assumes no backorder recapture. Management also flagged a lack of Mayfield head clamp inventory, which risks share loss to smaller competitors that may outlast the outage. The fourth-quarter revenue guide implies an organic decline of 0.4% to 5.1%, so headline growth is set to turn negative. The full-year gross margin outlook moved to roughly flat from 60 basis points of expansion.

The balance sheet is the clearest improvement. Operating cash flow reached a record $96 million, and free cash flow was $85.7 million, up from $10.5 million in the second quarter. Leverage fell to 3.8x from 4.5x at the end of 2025. The $2.1 billion refinancing pushed out maturities and widened covenant headroom, with the 2027 step-down now set at 4.25x instead of 4.0x. The price was steep, though. The new notes carry a 9.5% coupon, which adds about $8 million of interest in the fourth quarter and about $24 million in 2027. In July, management had suggested higher interest costs would be offset. Year-end leverage is now expected 'just above' 3.5x. On the catalyst side, the SurgiMend limited launch is still targeted for December, with a breast reconstruction PMA expected in 2027. That approval depends on a Braintree pre-approval inspection, and the sales force is slated to grow from about 30 to about 50 reps.

Investors have turned decisively more cautious. Earnings Whispers sentiment fell from roughly neutral at -0.07 to -0.30, a meaningful deterioration. Shares closed at $13.33 heading into the report, down 28% from the $18.51 open after the July release. That leaves the stock 5.4% below its 200-day moving average and about 30% below the $19.00 high set the day after the last report. The stock is 7.9% above the inter-earnings low of $12.35, set on October 5, just after the pre-announcement. The Earnings Whispers price and AVWAP trend readings remain negative, while momentum is neutral.

The bottom line is that Integra delivered an acceptable quarter that does little to repair a damaged outlook. Neurosurgery strength, record cash flow and the refinancing preserve a credible path that management says still includes revenue and some EPS growth in 2027. Bears have legitimate ammunition, however. The flood's cost keeps growing, Tissue Reconstruction is losing share, margins are contracting, and debt is now more expensive. With much of the bad news already reflected in the stock's slide, the next test is execution: restoring Cincinnati on schedule and getting SurgiMend relaunched without further slippage.